
Elevance Health Inc. (ELV), a large-cap health insurer, has achieved a 91% rating from Validea's Peter Lynch P/E/Growth Investor model, signaling strong interest from this strategy. The model, which seeks stocks with reasonable price relative to earnings growth and strong balance sheets, found ELV to pass key metrics like PEG ratio, EPS, and return on assets, despite neutral scores for debt/equity and free cash flow.
Elevance Health (ELV) has registered a strong 91% rating from Validea's Peter Lynch-based P/E/Growth model, indicating a high degree of alignment with this growth-at-a-reasonable-price (GARP) strategy. The positive assessment is driven by ELV passing key tests for its Yield Adjusted P/E to Growth (PEG) ratio and Earnings Per Share (EPS), suggesting an attractive valuation relative to its earnings growth. Furthermore, the company demonstrates sound profitability and efficiency, as reflected by its passing scores on Return on Assets and the Equity/Assets ratio. However, the model presents a more moderate view on the company's financial health and cash generation, with the Total Debt/Equity ratio, Free Cash Flow, and Net Cash Position all receiving a 'Neutral' rating. This suggests that while the balance sheet is not a point of significant concern, it does not exhibit the same level of strength as the company's growth and profitability metrics.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment